Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1 [0.03%]
一项关于新型JAK抑制剂Momelotinib对比Ruxolitinib在贫血的初治原发性骨髓纤维化患者中的脾脏体积缩小和减少输血依赖及对无劣效影响的Ⅲ期临床研究（SIMPLIFY-1）
Francesca Palandri,Nicolaas P M Schaap,Jerome Rey et al.
Francesca Palandri et al.
Introduction: Improvements in splenomegaly, anemia, and overall survival (OS) are key considerations in the management of patients with myelofibrosis. In the phase III SIMPLIFY-1 trial (NCT01969838), momelotinib was nonin...
Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study [0.03%]
奥雷巴替尼治疗慢性髓性白血病淋巴细胞急变期或费城染色体阳性难治复发急性淋巴细胞白血病的疗效：一项多中心回顾性研究
Mei Bao,Jian Huang,Zongru Li et al.
Mei Bao et al.
Objectives: To explore the efficacy and safety olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase (CML-LBP) or relapsed or refractory Philadelphia chromosome-positiv...
Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017 [0.03%]
在中东急性髓系白血病队列中验证欧洲白血病网2022年指南：与生存结局的相关性及与ELN 2017年的比较
Salem H Alshemmari,Ahmad AlSarraf,Reem Ameen et al.
Salem H Alshemmari et al.
Background: The European LeukemiaNet (ELN) guidelines are widely used for risk stratification in acutemyeloid leukemia (AML), but validation in non Western patients remains limited. ...
Refractory Burkitt Lymphoma Responding to an Accelerated Ramp-up of Glofitamab With Polatuzumab [0.03%]
接受戈利妥单抗联合波洛妥珠单抗加速爬坡治疗的难治性伯基特淋巴瘤患者的疗效
Syed Abdul Mannan Shah,Aaron Cumpston,Huda Elzahrany et al.
Syed Abdul Mannan Shah et al.
SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas [0.03%]
SOHO前沿更新及下一步问题 | 解析侵袭性B细胞淋巴瘤的变革性问题
Gonca Ozcan,Mark Roschewski
Gonca Ozcan
Large B-cell lymphoma (LBCL) is a heterogeneous disease for which anthracycline-based chemoimmunotherapy cures most patients. However, a substantial minority of patients experience refractory disease or relapse, and outcomes remain poor. Im...
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma [0.03%]
新型化疗方案与传统化疗方案治疗复发或难治性经典型霍奇金淋巴瘤的疗效比较研究
Daniel Ermann,Victoria Vardell,Erin Zacholski et al.
Daniel Ermann et al.
Background: Limited data exists comparing the efficacy of novel therapies containing brentuximab vedotin and/or checkpoint inhibitors to standard chemotherapy as treatment for relapsed/refractory classical Hodgkin Lymphom...
Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab [0.03%]
两例接受Elranatamab治疗的进行性多灶性白质脑病(PML)患者报告
Oliver Tomkins,Rea Grace Maamari,Sam Douthwaite et al.
Oliver Tomkins et al.
Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients [0.03%]
种族和民族对多发性骨髓瘤患者生存的社会驱动因素分析
Christen M Dillard,Ashwath Gurumurthi,Hans C Lee et al.
Christen M Dillard et al.
Background: Despite the introduction of novel antimyeloma therapies, Black and Hispanic individuals with multiple myeloma (MM) often experience worse survival outcomes than White counterparts, influenced not only by disea...
Real-World Insights Into Acute promyelocytic leukemia (APL) in Egypt in the Absence of Arsenic Trioxide (ATO): Clinical Characteristics, Outcomes and Risk Factors for Early Mortality: A Single Center Study [0.03%]
埃及真实世界急性早幼粒细胞白血病的临床特点、预后及早期死亡的影响因素：一项单中心研究（未使用三氧化砷）
Yasmine Shaaban,Dina N Laimon,Esraa Jamal
Yasmine Shaaban
Background: Acute promyelocytic leukemia (APL) is a rare but highly curable subtype of acute leukemia. Despite therapeutic advances, early death (ED) within 30 days of diagnosis remains a major challenge affecting APL out...
An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study [0.03%]
来那度胺和蛋白酶体抑制剂初治多发性骨髓瘤患者的治疗模式及疗效的观察性研究：Base-MM研究
Klaus Martin Kortüm,James Farrell,Olivia Ashman et al.
Klaus Martin Kortüm et al.
Introduction: Most patients with relapsed or refractory multiple myeloma (RRMM) have previously received lenalidomide (LEN) and proteasome inhibitors (PIs). This real-world study describes treatment patterns and clinical ...